IN8bio reports Q3 2026 results, adds SVP of R&D, advances TCE pipeline

IN8bio, Inc. reported financial results for the third quarter ended September 30, 2026, on November 5, 2026. The company said it remains on track to report initial in vivo preclinical data for INB-619 by year-end 2026.¹

The company strengthened its research leadership, bringing on Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development in September 2026, bringing 20 years of experience in γδ T cell biology, immunology, oncology, TCE and biologics development.¹ She previously served as Chief Scientific Officer at LAVA Therapeutics, a clinical-stage immuno-oncology company developing bispecific γδ T cell engagers.¹

On the pipeline, IN8bio said it is continuing to advance its proprietary INB-600 platform of novel pan-γδ T cell engagers designed to selectively engage and expand γδ T cells, including INB-619, which is moving through preclinical studies for potential use in oncology and autoimmune diseases.¹ A review published in October 2026, titled "next-generation immune cell engagers for B cell depletion in autoimmune disease" in Nature Reviews Drug Discovery, cited INB-619's capacity in lab studies to activate and expand both tissue-resident Vδ1 and circulating Vδ2 γδ T cells in vitro.¹

In July 2026, the company announced publication of Phase 1 clinical data for INB-200 (DeltEx DRI) in patients with newly diagnosed glioblastoma, in the Journal of Clinical Oncology, under the title "Intracranial injection of ex vivo expanded and activated gamma-delta T cells engineered with a MGMT-expressing lentivector in patients with primary glioblastoma."¹

Financially, the company had cash of $14.0 million as of September 30, 2026, compared with $10.7 million a year earlier.¹ It reported a net loss of $4.6 million, or $0.24 per basic and diluted share, versus a net loss of $3.9 million, or $0.85 per share, in the prior-year quarter.¹